MacroGenics, Inc.
NEWS
Two of the five fatalities were found to be unrelated to MacroGenics’ investigational antibody-drug conjugate vobra duo, while the other three are still under investigation.
Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers.
MacroGenics’ Phase II trial shuts down after a patient death believed to be related to enoblituzumab combo, while Exelixis’ Cabometyx combo improves PFS in renal cell carcinoma.
The study was assessing the investigational drug enoblituzumab as part of a combination therapy for head and neck cancer.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
The biopharmaceutical company announced the final overall survival analysis of its drug MARGENZA in SOPHIA Phase III study in adults with metastatic breast cancer.
The U.S. Food and Drug Administration (FDA) had several approvals this week. Read on to see what the regulatory agency gave the go-ahead to.
As the year wraps up, there are still some PDUFA dates on the agency’s calendar. Read on for this week’s.
To wrap up Breast Cancer Awareness Month, BioSpace gathered some examples of recent breakthroughs in breast cancer treatment.
JOBS
IN THE PRESS